Drug Trial Radar · NCT00590837
Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years Old
Last checked: Nov 20, 2026Latest source record: Apr 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
459
Actual
Start
Feb 2008
Primary completion
Dec 2012
Study completion Dec 2013
Sponsor
- Lead sponsor
- University Hospital, BordeauxAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 11, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter randomized trial comparing induction therapy (IC: Idarubicin and Cytarabine, 5 + 7) to ICL (the same drugs plus lomustine (CCNU), 200 mg/m2 orally at day 1). Patients in complete remission (CR) will then receive a post-remission schedule with or without lomustine according to randomization. Patients from 60 to 65 years old will be proposed to reduced conditioning allogeneic transplantation after first consolidation.
Conditions
- Acute Myeloid Leukemia
Interventions
LomustineDrug
Induction: chemotherapy + lomustine (CCNU), 200 mg/m2 orally at day 1. Consolidation: chemotherapy + lomustine (CCNU), 80 mg orally at day 1. Reinductions: chemotherapy + lomustine (CCNU), 40 mg orally at day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: 1 year
Locations
32 sites in 1 country. Site status is shown where the registry gives one.
Services maladies du sang, cancérologie, Hôpital Sud, CHU Amiens
Amiens, France
Service des maladies du sang, Centre Hospitalier Universitaire d'Angers
Angers, France
Service Hématologie, Centre Hospitalier Annecy
Annecy, France
C.H Victor Dupouy
Argenteuil, France
Service Médecine Interne, Onco-Hématologie, Maladies Infectieuses, Hôpital Henri Duffaut, Centre Hospitalier Avignon
Avignon, France
Service Hématologie, Centre Hospitalier de la Côte Basque
Bayonne, France
Service Hématologie, Hôpital Minjoz
Besançon, France
Unité Hématologie, Centre Hospitalier Blois
Blois, France
Service des maladies du sang - Hôpital Haut-Lévêque
Bordeaux - Pessac, France
Service Hématologie, Hôpital Dr Duchenne
Boulogne-sur-Mer, France
Service Hématologie, Hôpital Augustin Morvan
Brest, France
Service Hématologie et Thérapie cellulaire, Pavillon Villemin Pasteur, CHU Clermont-Ferrand
Clermont-Ferrand, France
Service Oncologie - Hématologie, Hôpital Pasteur, Centre Hospitalier Colmar
Colmar, France
Service Hématologie Clinique, CHU Dijon Hôpital des enfants
Dijon, France
Service Hématologie Clinique, Hôpital Michallon, CHU de Grenoble
Grenoble, France
Service Onco-Hématologie 3, Institut Paoli Calmettes
Marseille, France
Service Hématologie Oncologie, CHR Metz-Thionville
Metz, France
Service Hématologie Oncologie, Hôpital Lapeyronie, CHU de Montpellier
Montpellier, France
Département d'hématologie, Hôpital E.Muller, Centre Hospitalier de Mulhouse
Mulhouse, France
Service Hématologie Clinique, CHU -Hôtel Dieu
Nantes, France
Service Hématologie Clinique, Hôpital Archet 1
Nice, France
Service Médecine B - Unité Onco-hématologique, CHU Caremeau
Nîmes, France
Service Oncologie Médicale, Hôpital de la Source
Orléans, France
Unité d'Hématologie, Hôpital Cochin
Paris, France
Service Hématologie, CHG Saint Jean
Perpignan, France
Service Hématologie Clinique, Hôpital Robert Debre
Reims, France
Service Hématologie Clinique, Hôpital Pontchaillou
Rennes, France
Service d'Hématologie, Institut de Cancérologhie de la Loire
Saint Priez En Jarez, France
Département d'Hématologie et d'Oncologie, Hôpital CHRU de Hautepierre
Strasbourg, France
Service Hématologie, Hôpital Purpan
Toulouse, France
Service Hématologie Clinique, Hôpital Bretonneau
Tours, France
Service Hématologie - Médecine Interne, Hôpitaux de Brabois
Vandœuvre-lès-Nancy, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.